Her2 overexpression is frequently found in breast cancer and typically associated with poor prognosis; a Her2/Her3 heterodimer operates as an oncogenic unit that drives breast cancer proliferation [69], with the phosphorylated tyrosines in the intracellular tail of the catalytically inactive Her3 functioning as adapter scaffolds for intracellular kinases such as PI3K (Phosphoinositide 3-kinase) and PLC (Phospholipase C). Here, HSPG2 is linked to breast cancer.